Emerging evidence indicates the deubiquitinase USP22 regulates transcriptional activation
and modification of target substrates to promote pro-oncogenic phenotypes. Here, in vivo …

Background c-Myc, a well-established oncogene, plays an important role in the initiation and
progression of various cancers, including prostate cancer. However, its mechanism in …

Increasing evidence links deregulation of the ubiquitin-specific proteases 22 (USP22)
deubitiquitylase to cancer development and progression in a select group of tumor types, but …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly
malignancies. Recently, the deubiquitinating protease USP9X has been shown to behave …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. With an
overall five-year survival rate remaining below 6%, there is an explicit need to search for …

The androgen receptor (AR), a nuclear receptor superfamily transcription factor, plays a key
role in prostate cancer. AR signaling is the principal target for prostate cancer treatment, but …

Abstract Ubiquitin-specific protease 10 (USP10) is known to deubiquitylate its target
proteins, mainly to enhance their stabilities. USP10 maintains p53 protein levels and …

Abstract The Ki-67 antigen (Ki-67) is the most reliable immunohistochemical marker for
evaluation of cell proliferation in non-small cell lung cancer. However, the mechanisms …

The identification of therapeutic approaches to improve response to platinum-based
therapies is an urgent need for ovarian carcinoma. Deubiquitinases are a large family of …

Usp9x has emerged as a potential therapeutic target in some hematologic malignancies and
a broad range of solid tumors including brain, breast, and prostate. To examine Usp9x …